Article Text

Download PDFPDF
Orientation of Preclinical Research in Ovarian Cancer
  1. Thaïs Baert, MD*,,
  2. Abhishek D. Garg, PhD,
  3. Patrizia Agostinis, PhD,
  4. Ignace Vergote, MD, PhD*,§ and
  5. An Coosemans, MD, PhD*,
  1. *Department of Gynaecology and Obstetrics, Leuven Cancer Institute, University Hospitals Leuven; and
  2. Department of Oncology, Laboratory for Tumor Immunology and Immunotherapy, ImmunOvar Research Group,
  3. Department of Cellular and Molecular Medicine, Laboratory for Cell Death Research and Therapy, and
  4. §Department of Oncology, Laboratory of Gynaecological Oncology, KU Leuven, Leuven, Belgium.
  1. Address correspondence and reprint requests to Thaïs Baert, MD, ImmunOvar Research Group, Laboratory for Tumor Immunology and Immunotherapy, KU Leuven, O&N 1, 6th Floor, Box 603, Herestraat 49, 3000 Leuven, Belgium. E-mail:


Objectives A large variety of mouse models for cancer exist, also in the field of ovarian cancer. Each model possesses different features, which makes it difficult to interpret their translational value. This review provides an overview of the available ovarian cancer mouse models and their possible use in search for new treatments.

Methods This was a PubMed search of available literature on genetically engineered mouse models, xenografts, transplantable models, and immunocompetent mouse models in ovarian cancer, with a specific focus on clinically relevant features of the described models.

Results/Conclusions Several preclinical models are available for ovarian cancer. Based on their properties, a model should be carefully selected as a function of the experimental setup to achieve clinically relevant results.

  • Genetically engineered mouse models
  • ID8
  • Immunotherapy
  • Mouse model
  • Ovarian cancer
  • Xenograft

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.